<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04827563</url>
  </required_header>
  <id_info>
    <org_study_id>IRB20-1768</org_study_id>
    <nct_id>NCT04827563</nct_id>
  </id_info>
  <brief_title>Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib</brief_title>
  <official_title>Risk Factors for Dyspnea and Cardiotoxicity in Patients With Multiple Myeloma Who Receive Carfilzomib: A Prospective Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will explore why some multiple myeloma patients who receive carfilzomib (an&#xD;
      anti-cancer medication) experience shortness of breath while others do not. The purpose of&#xD;
      this research is to gather information on the effectiveness of the EndoPAT device, which is&#xD;
      FDA-approved to assess the health of a patient's blood vessels. These assessments will help&#xD;
      doctors leading the study determine the reasons why patients may develop shortness of breath&#xD;
      (dyspnea) when being treated with carfilzomib and ways to better prevent this shortness of&#xD;
      breath.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 22, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial Function and Dyspnea Associations in Multiple Myeloma Patients</measure>
    <time_frame>2 months</time_frame>
    <description>The association between baseline endothelial function and dyspnea in myeloma patients treated with carfilzomib. These associations will be assessed by comparing endothelial function within two cohorts: patients with abnormal baseline endothelial function, and patients with normal baseline endothelial function. Baseline endothelial function will be measured using EndoPat, an FDA-approved device used for health tests. Dyspnea rates will be assessed by participant-reported outcomes using the FACIT Dyspnea-10 Raw Dyspnea Score and Common Terminology Criteria for Adverse Events V5.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Toxicities Associated with Changes in Carfilzomib-Induced Endothelial Function</measure>
    <time_frame>2 months</time_frame>
    <description>The association between changes in carfilzomib-induced endothelial function and frequency of cardiovascular toxicities stratified by patients with abnormal and normal baseline endothelial function.Cardiovascular toxicities in this study will be defined as new or worsening symptomatic heart failure, hypertension, myocardial ischemia, stroke, pulmonary hypertension, arrhythmias and thromboembolic events that will be measured per CTCAE V5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Affects of Carfilzomib Dose/Dosing Schedule on the Incidence of Dyspnea</measure>
    <time_frame>2 months</time_frame>
    <description>The affects of carfilzomib dose/dosing schedule on how often participants experience dyspnea (shortness of breath) will be assessed by participant reported outcomes using the FACIT Dyspnea-10 (raw dyspnea score) and data collected on adverse events (side effects) using CTCAE V5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Cardiovascular Physiology and Risk Factors Associated with Endothelial Function</measure>
    <time_frame>2 months</time_frame>
    <description>To determine whether changes in endothelial function are associated with cardiovascular physiological changes and cardiovascular risk factors within participants receiving carfilzomib. These associations will be measured by: hemodynamics (using the average 24-hour ambulatory blood pressure reported by participants after treatment using home blood pressure monitoring), echocardiography using echocardiogram, and data collected on patient's vascular and cardiovascular health at baseline.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Shortness of Breath</condition>
  <condition>Dyspnea</condition>
  <condition>Cardiotoxicity</condition>
  <arm_group>
    <arm_group_label>Participants with Normal Baseline Endothelial Function</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants with Abnormal Baseline Endothelial Function</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EndoPAT</intervention_name>
    <description>An FDA approved device to test the health of a patient's blood vessels, which involves putting an oxygen probe on the participant's finger.</description>
    <arm_group_label>Participants with Abnormal Baseline Endothelial Function</arm_group_label>
    <arm_group_label>Participants with Normal Baseline Endothelial Function</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Blood Pressure Cuff</intervention_name>
    <description>A device used to conduct blood pressure monitoring using a home blood pressure cuff that participant wears for 24 hours.</description>
    <arm_group_label>Participants with Abnormal Baseline Endothelial Function</arm_group_label>
    <arm_group_label>Participants with Normal Baseline Endothelial Function</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Echocardiogram</intervention_name>
    <description>A test used to conduct an ultrasound of participant's heart.</description>
    <arm_group_label>Participants with Abnormal Baseline Endothelial Function</arm_group_label>
    <arm_group_label>Participants with Normal Baseline Endothelial Function</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality of Life Assessment</intervention_name>
    <description>A survey that will be given to participants to report their quality of life and symptoms related to multiple myeloma.</description>
    <arm_group_label>Participants with Abnormal Baseline Endothelial Function</arm_group_label>
    <arm_group_label>Participants with Normal Baseline Endothelial Function</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Tests</intervention_name>
    <description>Routinely collected for all participants who begin carfilzomib treatment.</description>
    <arm_group_label>Participants with Abnormal Baseline Endothelial Function</arm_group_label>
    <arm_group_label>Participants with Normal Baseline Endothelial Function</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with multiple myeloma who are being treated with carfilzomib.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18&#xD;
&#xD;
          -  Confirmed diagnosis of multiple myeloma&#xD;
&#xD;
          -  Newly-diagnosed multiple myeloma, or relapsed/refractory multiple myeloma with receipt&#xD;
             of 1-3 previous lines of therapy and with a 2-week washout from prior therapy&#xD;
&#xD;
          -  Receiving carfilzomib as either standard-of-care therapy or as part of a clinical&#xD;
             trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous receipt of anthracycline chemotherapy&#xD;
&#xD;
          -  Previous receipt of carfilzomib&#xD;
&#xD;
          -  Four or more previous lines of therapy&#xD;
&#xD;
          -  Active pregnancy at the time of enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeanne DeCara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago - Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeanne DeCara, MD</last_name>
    <phone>(773) 834-6664</phone>
    <email>cancerclinicaltrials@bsd.uchicago.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ajay Major, MD</last_name>
    <phone>(773) 834-6664</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

